title: Circulating OPG levels are reduced following infliximab treatment and correlate with CRP levels: is serum OPG a potential marker of IBD disease activity?
authors: Emanuela
authors: E
authors: Galliera
authors: Laura
authors: L
authors: de Girolamo
authors: Giada
authors: G
authors: Dogliotti
authors: Carlo
authors: C
authors: De Salvo
authors: Giulia
authors: G
authors: Tosetti
authors: Luca
authors: L
authors: Pastorelli
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis*; D016207:Cytokines / Q000097:blood; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000097:blood* / Q000188:drug therapy; D000069285:Infliximab; D053244:Osteoprotegerin / Q000097:blood*; D053245:RANK Ligand / Q000097:blood
chemical_list: D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D015415:Biomarkers; D016207:Cytokines; D053244:Osteoprotegerin; D053245:RANK Ligand; C506030:TNFRSF11B protein, human; C505688:TNFSF11 protein, human; D002097:C-Reactive Protein; D000069285:Infliximab